Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

NCT03409432 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Lymphomatoid Papulosis
Primary Cutaneous Anaplastic Large Cell Lymphoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide

Sponsor

John Reneau